Published in Gene Therapy Weekly, April 19th, 2001
The recently issued patent has specific claims covering immunization using DNA vaccines that are designed to synthesize the T-cell receptor (TCR) V(beta) specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key superantigen protein sequences from the V(beta) 3, V(beta) 14, and V(beta) 17 regions of the TCR present on the surface of these pathogenic T...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.